Johnson & Johnson Stock News

Spotlight Asset Group Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,573 shares of the companys stock after selling 249 shares during the period. Spotlight Asset Group []

But another study showed that the Sputnik, Sinopharm and Johnson & Johnson jabs had little effect on the variant

Destiny Wealth Partners LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 43.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,000 shares of the companys stock after selling 1,555 shares during the quarter. Destiny Wealth []

COVID-19 vaccines produced by Johnson & Johnson and China''s Sinopharm, as well as the Russian-made Sputnik V, were found to provide little or no protection against the newly emerging Omicron variant, according to a study out this week. Driving the news: The study, which was published as a preprint and isn''t yet peer-reviewed, found that just three out of 13 people who were fully vaccinated with China''s Sinopharm vaccine produced neutralizing antibodies against Omicron. One out of 12 people with the Johnson & Johnson vaccine exhibited neutralizing antibodies. None of the 11 with Russia''s Sputnik V vaccine revealed protection, per the study conducted by researchers at the University of Washington and Swiss drugmaker Humabs Biomed SA. The study also found that the best protection against Omicron appears to come from both having a prior COVID-19 infection and two doses of a Pfizer vaccine. The big picture: The study comes as COVID cases are surging around the globe, appearing to be driven by the new variant.

Those who do not have a booster shot will no longer have a valid vaccination certificate to travel within the EU nine months after their second dose, EU leaders decided on Thursday. People vaccinated with two doses of a coronavirus vaccine (or one, in the case of Johnson & Johnson) will be able to travel []

South Africa''s donation will add to the more than 100 million vaccine doses that have been donated to the African Union''s African Vaccination Acquisition Trust.

JJ''s performance review process involves frequent check-ins between managers and employees, and places a greater emphasis on future growth.

The doses, worth approximately $18 million, will be produced at the Aspen Pharmacare manufacturing facility and distributed to various African countries over the next year.

NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.

Johnson & Johnsons Covid vaccine was going to be the shot for the world. Now, under the weight of a mountain of bad PR, one wonders if the world will

Pfizers and Modernas vaccines are more effective and cause fewer serious side effects, new data show An advisory committee for the U.S. Centers for Disease Control and Prevention voted unanimously December 16 to recommend mRNA COVID-19 vaccines over Johnson & Johnsons shot. When there is a choice, people seeking a COVID-19 shot should be told []

The panel cited the risk of rare but sometimes fatal cases of blood clotting as well as a lower level of effectiveness against COVID-19 in the Johnson & Johnson shot

MISE & Agrave; DAY US health officials on Thursday night recommended that all adults get the COVID-19 vaccine with Pfizer and Moderna rather than Johnson & amp; Johnson, due to the risk of thrombosis from J & amp; J''s vaccine. The move, announced by the Centers for Disease Prevention and Control (CDC), is a blow [] The post Health officials recommend vaccination with Pfizer and Moderna rather than Johnson & Johnson first appeared on The Bobr Times .

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday. The strange clotting problem has caused nine confirmed deaths after J&J vaccinations while the Pfizer and Moderna vaccines don''t come with that risk and also appear more effective, advisers to the Centers for Disease Control and Prevention said. It''s an unusual move and the CDC''s director, Dr. Rochelle Walensky, must decide whether to accept the panel''s advice. Until now the U.S. has treated all three COVID-19 vaccines available to Americans as an equal choice, since large studies found they all offered strong protection and early supplies were limited. J&J''s vaccine initially was welcomed as a single-dose option that could be especially important for hard-to-reach groups like homeless people who might not get the needed second dose of the Pfizer or Moderna options. But the CDC''s …

The study discovered that Omicron''s ''extensive'' mutations can ''greatly compromise'' all major COVID-19 vaccines - Pfizer, Moderna, Johnson & Johnson and AstraZeneca.